A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind
A phase 2 trial of Ciltacabtagene autoleucel, Talquetamab, Daratumumab in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.
Overview
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma is a phase 2 interventional study registered as NCT06577025 by Janssen Research & Development, LLC, with 43 participants enrolled, started 2024-08-20 and due to reach its primary completion in 2030-09-02. Interventions recorded: Cilta-cel, Talquetamab, Daratumumab, Teclistamab, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal
Shares Talquetamab, Teclistamab, Daratumumab, Lenalidomide.
- TrialA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul
Shares Ciltacabtagene autoleucel, Bortezomib, Daratumumab, Lenalidomide.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Talquetamab, Teclistamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Talquetamab, Ciltacabtagene autoleucel, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez
Shares Talquetamab, Teclistamab, Bortezomib, Johnson & Johnson.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Talquetamab, Daratumumab, Johnson & Johnson, Multiple myeloma.
- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Talquetamab, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Teclistamab, Bortezomib, Johnson & Johnson, Multiple myeloma.